在患有慢性病,2型糖尿病和切除术史的人群中使用芬瑞
Jair Munoz Mendoza1, Matthew R Weir2, Stefan D Anker3
1Katz Family Division of Nephrology and Hypertension, Department of Medicine, and Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
Clinical journal of the American Society of Nephrology : CJASN
|January 14, 2026
概括
在患有慢性病 (CKD) 和2型糖尿病 (T2D) 且有切除病史的患者中,芬瑞有效降低了白尿. 该药物表现出一致的安全性,这表明它可能会延迟CKD的进展,无论之前的手术.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 在FIDELITY试验中,芬在慢性病 (CKD) 和2型糖尿病 (T2D) 患者中显示出显著的心血管和益.
- 在FIDELITY试验的后期分析中,研究了finerenone在特定亚组的疗效和安全性:患有CKD,T2D和切除术病史的患者.
研究的目的:
- 评估芬在减少CKD,T2D和切除术病史患者的白蛋白尿症中的功效.
- 在这个患者亚组中评估芬的安全性,并将其与整体FIDELITY人群进行比较.
主要方法:
- 来自FIDELITY试验的患者根据他们的切除术状态进行了分析.
- 从基线到24个月时,尿中白蛋白与肌素比率 (UACR) 的变化被建模成模型,以评估CKD进展情况.
- 监测了安全结果,包括治疗出现的不良事件 (TEAE) 和高血症.
主要成果:
- 在108名患者中存在切除术史,其中55名患者接受了finerenone,53名患者接受了安慰剂.
- 与安慰剂 (1.09) 相比,芬瑞治疗在4个月后导致UACR显著降低 (与基线的最小平方平均比,0.65),这种益处持续了两年.
- 患有TEAE的发病率在有和没有腎切除病史的患者之间是可比的. 超血症发生在7%的费内伦治疗患者中,而在有腎切除史的安慰剂治疗患者中,这一比例为6%.
结论:
- 菲内伦有效地减少了CKD和T2D患者的专尿症,而不管他们有过切除术的病史.
- 该药物表现出与更广泛的FIDELITY试验人群相一致的安全性.
- 费内伦具有延迟CKD进展和CKD和T2D患者的相关并发症的潜力,无论之前的腎切除术如何.
相关概念视频
01:11Renal Failure: Dose Adjustments
437
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
437
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:28Chronic Kidney Disease III: Interprofessional Care
344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
01:24Chronic Kidney Disease II: Clinical Manifestations
555
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
555
01:17Factors Affecting Renal Clearance: Renal Impairment
425
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
425
01:25Chronic Kidney Disease I: Introduction
565
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
565